Genetics and the clinical response to warfarin and edoxaban: Findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial

The Lancet

Volumn 385, Issue 9984, 2015, Pages 2280-2287

  Mega, Jessica L ^a   Walker, Joseph R ^c   Ruff, Christian T ^a   Vandell, Alexander G ^b   Nordio, Francesco ^a   Deenadayalu, Naveen ^a   Murphy, Sabina A ^a   Lee, James ^b   Mercuri, Michele F ^b   Giugliano, Robert P ^a   Antman, Elliott M ^a   Braunwald, Eugene ^a   Sabatine, Marc S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DAIICHI SANKYO INC   (United States)

^c CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDOXABAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; CYTOCHROME P450 2C9; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE; VITAMIN K EPOXIDE REDUCTASE; VKORC1 PROTEIN, HUMAN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT RESPONSE; BLEEDING; CHEMICALLY INDUCED; COMPLICATION; GENETICS; PHARMACOGENETICS; RISK ASSESSMENT; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CYTOCHROME P-450 CYP2C9; DOUBLE-BLIND METHOD; FACTOR XA INHIBITORS; GENETIC VARIATION; GENOTYPE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; PHARMACOGENETICS; PYRIDINES; RISK ASSESSMENT; STROKE; THIAZOLES; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84934298609     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61994-2     Document Type: Article

References (41)

1. MA Crowther, J Julian, D McCarty et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial Lancet 356 2000 1551 1553
2. DS Budnitz, DA Pollock, KN Weidenbach, AB Mendelsohn, TJ Schroeder, JL Annest National surveillance of emergency department visits for outpatient adverse drug events JAMA 296 2006 1858 1866
3. DK Wysowski, P Nourjah, L Swartz Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action Arch Intern Med 167 2007 1414 1419
4. JA Johnson, L Gong, M Whirl-Carrillo et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing Clin Pharmacol Ther 90 2011 625 629
5. Food and Drug Administration Coumadin tablets (warfarin sodium tablets, USP) crystalline Coumadin for injection (warfarin sodium for injection, USP) http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/009218s108lbl.pdf (accessed March 3, 2015).
6. EMC Marevan 5 mg tablets http://www.medicines.org.uk/EMC/medicine/21596/SPC/Marevan+5mg+tablets/ May 26, 2014 (accessed March 3, 2015).
7. MJ Kim, SM Huang, UA Meyer, A Rahman, LJ Lesko A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity J Clin Pharmacol 49 2009 138 146
8. I Zineh, M Pacanowski, J Woodcock Pharmacogenetics and coumarin dosing - recalibrating expectations N Engl J Med 369 2013 2273 2275
9. SJ Connolly, MD Ezekowitz, S Yusuf et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
10. G Pare, N Eriksson, T Lehr et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding Circulation 127 2013 1404 1412
11. MR Patel, KW Mahaffey, J Garg et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
12. CB Granger, JH Alexander, JJ McMurray et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
13. CT Ruff, RP Giugliano, E Braunwald et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Lancet 383 2014 955 962
14. RP Giugliano, CT Ruff, E Braunwald et al. Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2013 2093 2104
15. BF Gage, AD Waterman, W Shannon, M Boechler, MW Rich, MJ Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
16. CT Ruff, RP Giugliano, EM Antman et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48) Am Heart J 160 2010 635 641
17. FR Rosendaal, SC Cannegieter, FJ van der Meer, E Briet A method to determine the optimal intensity of oral anticoagulant therapy Thromb Haemost 69 1993 236 239
18. R Pisters, DA Lane, R Nieuwlaat, CB de Vos, HJ Crijns, GY Lip A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
19. AJ Camm, GY Lip, R De Caterina et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation - developed with the special contribution of the European Heart Rhythm Association Europace 14 2012 1385 1413
20. JL Anderson, BD Horne, SM Stevens et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II) Circulation 125 2012 1997 2005
21. M Pirmohamed, G Burnside, N Eriksson et al. A randomized trial of genotype-guided dosing of warfarin N Engl J Med 369 2013 2294 2303
22. TI Verhoef, G Ragia, A de Boer et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon N Engl J Med 369 2013 2304 2312
23. UI Schwarz, MD Ritchie, Y Bradford et al. Genetic determinants of response to warfarin during initial anticoagulation N Engl J Med 358 2008 999 1008
24. TE Klein, RB Altman, N Eriksson et al. Estimation of the warfarin dose with clinical and pharmacogenetic data N Engl J Med 360 2009 753 764
25. CR Lee, JA Goldstein, JA Pieper Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data Pharmacogenetics 12 2002 251 263
26. MJ Rieder, AP Reiner, BF Gage et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose N Engl J Med 352 2005 2285 2293
27. Centers for Medicaid and Medicare Services Decision memo for pharmacogenomic testing for warfarin response (CAG-00400N) http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=224&NcaName=Pharmacogenomic+Testing+for+Warfarin+Response&NCDId=333&IsPopup=y&bc=AAAAAAAAAgAAAA%3D%3D& (accessed Feb 3, 2015).
28. GP Aithal, CP Day, PJ Kesteven, AK Daly Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Lancet 353 1999 717 719
29. M Margaglione, D Colaizzo, G D'Andrea et al. Genetic modulation of oral anticoagulation with warfarin Thromb Haemost 84 2000 775 778
30. MK Higashi, DL Veenstra, LM Kondo et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy JAMA 287 2002 1690 1698
31. LM Meckley, AK Wittkowsky, MJ Rieder, AE Rettie, DL Veenstra An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients Thromb Haemost 100 2008 229 239
32. K Lund, D Gaffney, R Spooner, AM Etherington, P Tansey, RC Tait Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin international normalized ratio control and bleeding rates Br J Haematol 158 2012 256 261
33. AL Jorgensen, RJ FitzGerald, J Oyee, M Pirmohamed, PR Williamson Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis PLoS One 7 2012 e44064
34. JA Roth, D Boudreau, MM Fujii et al. Genetic risk factors for major bleeding in patients treated with warfarin in a community setting Clin Pharmacol Ther 95 2014 636 643
35. US Food and Drug Administration FDA drug safety communication: update on the risk for serious bleeding events with the anticoagulant Pradaxa (dabigatran) http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm Feb 11, 2012 (accessed Feb 3, 2015).
36. CT January, LS Wann, JS Alpert et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society J Am Coll Cardiol 64 2014 e1 76
37. MA Perera, LH Cavallari, NA Limdi et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study Lancet 382 2013 790 796
38. SE Kimmel, B French, SE Kasner et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing N Engl J Med 369 2013 2283 2293
39. C van Walraven, A Jennings, N Oake, D Fergusson, AJ Forster Effect of study setting on anticoagulation control: a systematic review and metaregression Chest 129 2006 1155 1166
40. WL Baker, DA Cios, SD Sander, CI Coleman Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States J Manag Care Pharm 15 2009 244 252
41. AJ Rose, EM Hylek, A Ozonoff, AS Ash, JI Reisman, DR Berlowitz Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA) Circulation Cardiovascular Qual Outcomes 4 2011 22 29